Kala Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call

Rhea-AI Summary

Kala Pharmaceuticals (NASDAQ:KALA) will announce its fourth quarter and full year 2021 financial results on March 29, 2022. Management will host a conference call at 8:00 a.m. ET to discuss these results and provide a business update. The call can be accessed via domestic and international dial-in numbers or through a live webcast on the company’s website.

Kala focuses on innovative therapies for eye diseases, with products like EYSUVIS® and INVELTYS® using its proprietary AMPPLIFY® drug delivery technology, alongside a pipeline for unmet medical needs.

Positive

• Kala has received attention for its innovative drug delivery technology, AMPPLIFY®, enhancing drug efficacy in treating ocular diseases.
• The company's product offerings, EYSUVIS® and INVELTYS®, position it well in the competitive ophthalmic market.
• Upcoming financial results may present potential for positive market reactions.

Negative

• None.

ARLINGTON, Mass., March 23, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will report fourth quarter and full year 2021 financial results on Tuesday, March 29, 2022. Management will host a conference call and live audio webcast to discuss these results and provide a business update at 8:00 a.m. ET.

The dial-in numbers to access the conference call are 866-300-4091 (domestic) or 703-736-7433 (international) using the conference ID 7368936. To access a live webcast and subsequent archived recording of the call, please visit “Events” in the “Investors” section on the Kala website at http://kalarx.com/.

About Kala Pharmaceuticals, Inc.

Kala is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for diseases of the eye. Kala has applied its AMPPLIFY® mucus-penetrating particle (MPP) Drug Delivery Technology to two ocular therapies, EYSUVIS® (loteprednol etabonate ophthalmic suspension) 0.25% and INVELTYS® (loteprednol etabonate ophthalmic suspension) 1%. Kala also has a pipeline of development programs including a clinical-stage secretome product candidate, KPI-012, initially targeting persistent corneal epithelial defects (PCED) and multiple proprietary new chemical entity (NCE) preclinical development programs targeted to address unmet medical needs, including both front and back of the eye diseases. For more information on Kala, please visit www.kalarx.com.

Investor Contacts:
Jill Steier
jill.steier@kalarx.com
781-996-5252

Hannah Deresiewicz
hannah.deresiewicz@sternir.com
212-362-1200

FAQ

When will Kala Pharmaceuticals report its financial results for 2021?

Kala Pharmaceuticals will report its fourth quarter and full year 2021 financial results on March 29, 2022.

How can I access the Kala Pharmaceuticals conference call?

You can access the conference call by dialing 866-300-4091 for domestic calls or 703-736-7433 for international calls, using conference ID 7368936.

What therapies does Kala Pharmaceuticals focus on?

Kala Pharmaceuticals focuses on innovative therapies for diseases of the eye, including products like EYSUVIS® and INVELTYS®.

What is the purpose of the upcoming conference call on March 29, 2022?

The conference call will discuss the fourth quarter and full year 2021 financial results and provide a business update.